C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
  • Publication number: 20140171474
    Abstract: The present invention relates to N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives of formula (I) wherein A, Z1, Z2, Z3, X, n, Y and m represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions
    Type: Application
    Filed: February 19, 2014
    Publication date: June 19, 2014
    Inventors: Philippe DESBORDES, Ralf DUNKEL, Stephanie GARY, Marie-Claire GROSJEAN-COURNOYER, Benoit HARTMANN, Philippe RINOLFI, Jean-Pierre VORS, Rachel RAMA
  • Publication number: 20140171308
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171314
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Patent number: 8754118
    Abstract: [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. [Means for Resolution] An atropisomer of a compound represented by the following general formula (I): (wherein R1 is a C1-C3 alkyl group or a hydroxy-C1-C3 alkyl group; and R2 is a hydrogen atom or a C1-C3 alkoxy group).
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: June 17, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kazumasa Aoki, Hiroyuki Tsuruoka, Noriyuki Hayashi, Juri Yoshida, Yusuke Asoh
  • Publication number: 20140155377
    Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian W. Metcalf, Amy Qi Han, Darius J. Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
  • Publication number: 20140155455
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Publication number: 20140155433
    Abstract: Disclosed is a compound of formula (I): wherein ‘D’, ‘E’, ‘m’, ‘n’ and R1-R4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.
    Type: Application
    Filed: July 2, 2012
    Publication date: June 5, 2014
    Applicant: LUPIN LIMITED
    Inventors: Neelima Sinha, Navnath Popat Karche, Girish Dhanraj Hatnapure, Anil Kashiram Hajare, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20140148383
    Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.
    Type: Application
    Filed: January 4, 2014
    Publication date: May 29, 2014
    Applicant: NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING
    Inventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
  • Patent number: 8734769
    Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: May 27, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Richard T. Lee
  • Patent number: 8735633
    Abstract: A method comprising reacting glycerol with acetaldehyde or 1,1-diethoxyethane to produce 1,3-dihydroxyacetone (DHA), without using fermentation or direct oxidation of the glycerol is provided. DHA is useful in various products, including as a sunless tanning agent.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: May 27, 2014
    Assignee: Board of Trustees of Michigan State University
    Inventors: Dennis Miller, Xi Hong, Carl Lira, Omar McGiveron
  • Publication number: 20140142127
    Abstract: Disclosed are stable formulations of omega-3 oils and HMG-CoA reductase inhibitors. The invention comprises an omega-3 oil, a salt form of an HMG-CoA reductase inhibitor, and a salt. These compositions are stable in liquid form useful for combination therapy.
    Type: Application
    Filed: October 22, 2013
    Publication date: May 22, 2014
    Applicant: Almburg, LLC
    Inventor: Orn Almarsson
  • Publication number: 20140140944
    Abstract: Disclosed is a composition of ion-exchange resins made from a styrene-divinylbenzene copolymer or an acrylic-divinylbenzene copolymer filled with at least one lipoaminoacid with the formula (I), in which R1 is the chain characterising a fatty acid, saturated or unsaturated, linear or branching, including 7 to 21 atoms of carbon, R2 is the chain characterising an amino acid and m is between 1 and 50, or a mixture of the compounds with the formula (I).
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
    Inventor: Yves DUCCINI
  • Publication number: 20140142145
    Abstract: The present invention is directed to a combination comprising a dipeptidylpeptidase-IV (DPP-IV) inhibitor in free or pharmaceutically acceptable form, and at least one further antidiabetic compound or the pharmaceutically acceptable salt of such a compound, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV, such as impaired glucose tolerance, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis, and preferably diabetes, especially type 2 diabetes mellitus.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 22, 2014
    Inventors: Bork Balkan, Thomas Edward Hughes, David Grenville Holmes, Edwin Bemard Villhauer
  • Publication number: 20140135321
    Abstract: Described herein are compounds, compositions, and methods for treating HIV and related diseases.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Inventor: Arun K. GHOSH
  • Patent number: 8722725
    Abstract: The present invention provides caffeoylquinic acid derivatives and a method of preparing for the same, and also provides pharmaceutical compositions containing caffeoylquinic acid derivatives, and uses of caffeoylquinic acid derivatives in preparation of a medicament for the treatment or prophylaxis of virus diseases, in particular, uses of respiratory syncytial virus and hepatitis B virus, which has the characteristics of safety, high effectiveness and low toxicity.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 13, 2014
    Assignee: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
    Inventors: Wu Zhanggui, Wei Wei
  • Publication number: 20140127295
    Abstract: The present disclosure describes a composition and a kit having a plurality of compounds for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as Rheumatoid Arthritis (RA). The disclosure also relates to a process of obtaining the composition and the method of treating diseases by administration of the compositions.
    Type: Application
    Filed: March 7, 2012
    Publication date: May 8, 2014
    Applicants: Cellworks Group, Inc, Cellworks Research India Private Limited
    Inventors: Shireen Vali, Robinson Vidva, Prashant Ramachandran Nair, Pradeep Fernandes, Taher Abbasi, Saumya Radhakrishnan
  • Publication number: 20140128436
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Application
    Filed: November 8, 2013
    Publication date: May 8, 2014
    Applicant: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • Publication number: 20140128437
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicants: President and Fellows of Harvard College, TRUSTEES OF BOSTON UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Tufts University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterrev, John A. Proco, JR.
  • Publication number: 20140128427
    Abstract: Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11?-hydroxystreroid dehydrogenase type 1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11?-hydroxystreroid dehydrogenase type 1.
    Type: Application
    Filed: June 11, 2012
    Publication date: May 8, 2014
    Applicant: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Coo-Min Chung, Choon-Ho Ryu, Yoon-Kyeong Lee, Jin-Sook Moon, Hye-Sung Lee, Seon-Jeong Lee, Kyung-Seok Oh
  • Patent number: 8716494
    Abstract: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 6, 2014
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Hiufung Chu, Antoni Krasinski, Christopher W. Lange, Manmohan R. Leleti, Jay P. Powers, Sreenivas Punna, Timothy J. Sullivan, Solomon Ungashe
  • Publication number: 20140121166
    Abstract: Provided are materials and methods for the prevention and treatment of Juvenile Neuronal Ceroid Lipofuscinosis comprising administration of an effective amount of at least one of a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor. In some embodiments, the methods comprise administration of an effective amount of each of a hemi-channel inhibitor and a phosphodiesterase-4 inhibitor. Also provided are pharmaceutical compositions comprising a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor, as well as kits comprising at least one effective dose of a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor or a combination of both.
    Type: Application
    Filed: October 29, 2013
    Publication date: May 1, 2014
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventor: Tammy Kielian
  • Publication number: 20140120112
    Abstract: The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 1, 2014
    Inventor: Kameran Lashkari
  • Publication number: 20140121260
    Abstract: The present application discloses conjugates comprising an aminic moiety covalently linked to a hydrophobic moiety, through an amidic bond, which are selective inhibitors of COX-2 enzyme and can be beneficially used in the treatment of various inflammatory disease or disorder and cancer.
    Type: Application
    Filed: January 6, 2014
    Publication date: May 1, 2014
    Applicant: MedWell Laboratories Ltd.
    Inventors: Taher NASSAR, Raiyn Nureldin, Rayan Anwar
  • Publication number: 20140121229
    Abstract: The invention provides a combination comprising (a) S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate or prodrug of the active form thereof, and (b) at least one HMG CoA reductase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the aforementioned active ingredients.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 1, 2014
    Applicant: Japan Tobacco Inc.
    Inventor: Japan Tobacco Inc.
  • Publication number: 20140121217
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 1, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Lijun Sun, Jun Jiang, Yu Xie
  • Patent number: 8710241
    Abstract: The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: April 29, 2014
    Assignee: Generics [UK]Limited
    Inventor: Axel Becker
  • Patent number: 8710002
    Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: April 29, 2014
    Inventor: Michael Rothkopf
  • Publication number: 20140113948
    Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 24, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 8697741
    Abstract: A process for the preparation of amorphous atorvastatin calcium. The process includes providing a reaction mixture having a pH between 6.5 and 8.0 containing a sodium salt of atorvastatin and tetrahydrofuran. A non-cyclic chlorinated organic solvent selected from the group consisting of dichloromethane, trichloroethane, tetrachloroethane and chloroform or addition of cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane and methyl cyclohexane is added to provide a mixture of organic solvents. An equivalent or an excess quantity of a source of calcium ions selected from the group consisting of calcium acetate and calcium chloride is added. Amorphous atorvastatin calcium is isolated from an organic phase comprising the mixture of organic solvents.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: April 15, 2014
    Assignee: LEK Pharmaceutical D.D.
    Inventors: Ljubomir Antoncic, Gorazd Sorsak, Anton Copar
  • Publication number: 20140100227
    Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 10, 2014
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Christopher F. BENDER, Xin JIANG, Eric ANDERSON, Melean VISNICK
  • Publication number: 20140100260
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 10, 2014
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Patent number: 8691861
    Abstract: This invention provides new pharmaceutically useful compounds that are prodrugs of inhibitors of plasma kallikrein and methods and compositions for preventing or treating plasma kallikrein dependent diseases or conditions, such as diabetic macular edema or hemorrhagic stroke, by administering prodrugs of the formula:
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 8, 2014
    Assignee: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote, Joghee Raju Suresh, Sriram Narasimhan
  • Publication number: 20140094434
    Abstract: Amino acid compositions containing a carbohydrate and any one or more kinds of alanine, proline and glycine as amino acid can suppress a rapid increase in the blood glucose level immediately after ingestion and a decrease in the blood glucose level due to prolonged exercise, and can improve exercise performance. In addition, the present invention provides inhibitors of an increase in the blood glucose level immediately after carbohydrate ingestion, an inhibitor of a decrease in the blood glucose level due to a prolonged exercise, and an exercise performance improver. Therefore, the present invention provides an energy supplement useful for those who exercise (particularly prolonged exercise).
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yuri HIRABAYASHI, Chie FURUTA, Yoshihito NOGUSA, Katsuya SUZUKI, Hisamine KOBAYASHI
  • Publication number: 20140093513
    Abstract: The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 3, 2014
    Applicant: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu
  • Patent number: 8686163
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 1, 2014
    Assignee: Pfizer Inc.
    Inventors: Antone J deBettencourt, III, Evgenyi Shalaev, George J. Quallich, Carl B. Ziegler, Jr.
  • Patent number: 8686026
    Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 1, 2014
    Assignee: AbbVie Inc.
    Inventors: Bernd Liepold, Tina Jung, Peter Hölig, Rudolf Schroeder, Nancy E. Sever, Justin S. Lafountaine, Brent D. Sinclair, Yi Gao, Jianwei Wu
  • Publication number: 20140088074
    Abstract: Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
    Type: Application
    Filed: May 29, 2012
    Publication date: March 27, 2014
    Applicant: NEWRON PHARMACEUTICALS S.P.A.
    Inventor: Paolo Pevarello
  • Patent number: 8680127
    Abstract: The present invention relates to N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives of formula (I) wherein A, Z1, Z2, Z3, X, n, Y and m represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: March 25, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Philippe Desbordes, Ralf Dunkel, Stephanie Gary, Marie-Claire Grosjean-Cournoyer, Benoit Hartmann, Philippe Rinolfi, Jean-Pierre Vors, Rachel Rama
  • Patent number: 8680100
    Abstract: The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds are also included.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 25, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Teresa Kowalczyk-Przewloka, Stefan M. Schweizer, Zhi-Qiang Xia, Shoujun Chen, Christopher Borella, Lijun Sun
  • Publication number: 20140079826
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing human growth hormone (hGH) levels in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Publication number: 20140080889
    Abstract: A method and composition for lipid therapy. In some embodiments, the method comprises providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: George BOBOTAS, Roelof M. Rongen, Egil Bodd, Hogne Vik
  • Publication number: 20140079830
    Abstract: Embodiments of the invention generally relate to methods for improving thyroid function in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • Publication number: 20140079825
    Abstract: A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. HEATON, Mitchell K. Friedlander, Dennis Gay
  • Publication number: 20140079823
    Abstract: Embodiments herein relate to nutritional supplements for treating post-traumatic stress disorder in human beings, and to methods of using the same. In particular examples, the nutritional supplement comprises an amino acid secretagogue composition.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • Publication number: 20140079831
    Abstract: Embodiments of the invention generally relate to supplements for increasing human growth hormone (hGH) levels in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Quality IP Holdings, LLC
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Publication number: 20140080888
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing endurance and fat metabolism in human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • Publication number: 20140079822
    Abstract: Embodiments of the invention generally relate to methods and supplements for improving sleep efficiency in human beings.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • Publication number: 20140079827
    Abstract: A method of improving health in an animal includes administering to the animal a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland in the animal to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Publication number: 20140080887
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing linear growth in borderline GH deficient and non-GH deficient children.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Publication number: 20140080802
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 20, 2014
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang